Muscular Dystrophy is a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing them to weaken and deteriorate over time. The most common form of muscular ...

The Duchenne muscular dystrophy market is witnessing steady growth driven by advancements in gene therapies, exon-skipping drugs, and corticosteroid alternatives. Increasing diagnosis rates, rising ...

Dr. Michael Rudnicki's findings on Duchenne muscular dystrophy set the stage for the development of a drug now entering clinical trials. By Elizabeth Payne Published Nov 26, 2024 ...

Agamree, an approved steroid treatment for Duchenne MD, will be sold in Turkey by GEN, per an agreement with Santhera.

Dr Essajee says that in Kenya, treatment is largely supportive: “Steroids like Deflazacort, combined with vitamin D and ...

Ann & Robert H.Lurie Children’s Hospital of Chicago treated its first Duchenne muscular dystrophy patient on March 27, 2024with ELEVIDYS (received U.S. Food and Drug Administration (FDA ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...

COALITION Duchenne's 13th annual Expedition Mt Kinabalu will start tomorrow from Shangri-La's Tanjung Aru Resort and Spa, ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials to keep an eye on in 2025.

Parent Project Muscular Dystrophy fights to end Duchenne. We accelerate research, raise our voices to impact policy, demand optimal care for every single family, and strive to ensure access to ...